PLoS ONE (Jun 2010)

Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia.

  • Alexander Hoare,
  • Stephen J Kerr,
  • Kiat Ruxrungtham,
  • Jintanat Ananworanich,
  • Matthew G Law,
  • David A Cooper,
  • Praphan Phanuphak,
  • David P Wilson

DOI
https://doi.org/10.1371/journal.pone.0010981
Journal volume & issue
Vol. 5, no. 6
p. e10981

Abstract

Read online

Universal access to first-line antiretroviral therapy (ART) for HIV infection is becoming more of a reality in most low and middle income countries in Asia. However, second-line therapies are relatively scarce.We developed a mathematical model of an HIV epidemic in a Southeast Asian setting and used it to forecast the impact of treatment plans, without second-line options, on the potential degree of acquisition and transmission of drug resistant HIV strains. We show that after 10 years of universal treatment access, up to 20% of treatment-naïve individuals with HIV may have drug-resistant strains but it depends on the relative fitness of viral strains.If viral load testing of people on ART is carried out on a yearly basis and virological failure leads to effective second-line therapy, then transmitted drug resistance could be reduced by 80%. Greater efforts are required for minimizing first-line failure, to detect virological failure earlier, and to procure access to second-line therapies.